Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Celsion OK'd for China Phase III Trial of Liver Cancer Treatment

publication date: Dec 16, 2015
Celsion of New Jersey received CFDA approval to conduct China clinical trials of its liver cancer drug, ThermoDox®, as part of a Phase III global study. ThermoDox is Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. In 2013, ThermoDox failed a Phase III trial when it didn't increase survival, but a retrospective analysis suggested longer heat-activation treatment would improve results. Zhejiang Hisun Pharma (SHA: 600267) of China has first rights to bid on marketing the drug in China. More details....

Stock Symbol: (NSDQ: CLSN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital